Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)


  • Silvia Calabria Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Manenti Lucio Azienda Socio-Sanitaria Liguria 5, Nephrology Unit, La Spezia - Italy
  • Giulia Ronconi Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Carlo Piccinni Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Leonardo Dondi Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Letizia Dondi Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Antonella Pedrini Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Immacolata Esposito Drugs and Health Srl, Roma - Italy
  • Alice Addesi Drugs and Health Srl, Roma - Italy
  • Filippo Aucella Medical Sciences Department, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo (FG) - Italy
  • Nello Martini Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy



Costs, Dialysis, End-stage kidney disease, Italy, Retrospective analysis, RWE, Treatment, Uremic pruritus


Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data.

Methods: Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS).

Results: Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost.

Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.


Download data is not yet available.


Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med. 2020;3(1):42-53.e1. PMID:33604539 DOI:

Kim D, Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J. 2021 Oct;14(suppl 3):i1-i7. DOI:

van der Willik EM, Lengton R, Hemmelder MH, et al. Itching in dialysis patients: impact on health-related quality of life and interactions with sleep problems and psychological symptoms—results from the RENINE/PROMs registry. Nephrol Dial Transplant. 2022;37(9):1731-1741. PMID:35098998 DOI:

Kimata N, Fuller DS, Saito A, et al. Pruritus in hemodialysis patients: results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS). Hemodial Int. 2014;18(3):657-667. PMID:24766224 DOI:

Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685-691. PMID:24402092 DOI:

Millington GWM, Collins A, Lovell CR, et al. British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018. Br J Dermatol. 2018;178(1):34-60. PMID:29357600 DOI:

Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469-506. PMID:30931482 DOI:

Ting SW, Fan PC, Lin YS, et al. Association between uremic pruritus and long-term outcomes in patients undergoing dialysis. J Am Acad Dermatol. 2020;83(3):924-925. PMID:31940463 DOI:

Aresi G, Rayner HC, Hassan L, et al. Reasons for underreporting of uremic pruritus in people with chronic kidney disease: a qualitative study. J Pain Symptom Manage. 2019;58(4):578-586.e2. PMID:31228535 DOI:

Istituto Nazionale di Statistica and ISTAT. Resident population by age, sex and marital status. 2015. Accessed December 2023.

Piccinni C, Cevoli S, Ronconi G, et al. Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs. Expert Rev Clin Pharmacol. 2021;14(9):1165-1171. PMID:34030566 DOI:

Maggioni AP, Dondi L, Andreotti F, et al. Prevalence, clinical impact and costs of hyperkalaemia: special focus on heart failure. Eur J Clin Invest. 2021;51(8):e13551. PMID:33786826 DOI:

Ronconi G, Dondi L, Calabria S, et al. Real-world prescription pattern, discontinuation and costs of ibrutinib-naïve patients with chronic lymphocytic leukemia: an Italian healthcare administrative database analysis. Clin Drug Investig. 2021;41(7):595-604. PMID:34032988 DOI:

WHO. Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. Accessed May 2023.

Ministero del Lavoro, della salute e delle politiche sociali. Classificazione delle malattie, dei traumatismi, degli interventi chirurgici e delle procedure dagnostiche e terapeutiche. Versione italiana della ICD9-CM. 2007. Accessed December 2023.

CINECA—Interuniversity Consortium. Accessed May 2023.

Società Italiana di Nefrologia. Registro italiano di dialisi e trapianto [Italian Registry of Dialysis and Transplantation]. Accessed May 2023.

Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5(9):1387-1402. PMID:32954065 DOI:

Simonsen E, Komenda P, Lerner B, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017 Nov;70(5):638-655. PMID:28720208 DOI:

van Oosten MJM, Logtenberg SJJ, Edens MA, et al. Health claims databases used for kidney research around the world. Clin Kidney J. 2020;14(1):84-97. PMID:33564408 DOI:

Agenzia Italiana del Farmaco. Nota 89. GU Serie Generale n.259 del 04-11-2004 2004. Accessed December 2023.

Agenzia Italiana del Farmaco. Nota 4. Farmaco in nota: duloxetina, gabapentin, pregabalin. Accessed December 2023.

Arzhan S, Roumelioti ME, Unruh ML. Itch and ache on dialysis: new approaches to manage uremic pruritus and restless legs. Blood Purif. 2020;49(1-2):222-227. PMID:31851986 DOI:

Trachtenberg AJ, Collister D, Rigatto C. Recent advances in the treatment of uremic pruritus. Curr Opin Nephrol Hypertens. 2020;29(5):465-470. PMID:32740217 DOI:

Additional Files



How to Cite

Calabria, S., Lucio, M., Ronconi, G., Piccinni, C., Dondi, L., Dondi, L., Pedrini, A., Esposito, I., Addesi, A., Aucella, F., & Martini, N. (2024). Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP). Global and Regional Health Technology Assessment, 11(1), 22–30.



Original Research Articles


Received 2023-10-24
Accepted 2023-11-29
Published 2024-01-15


Most read articles by the same author(s)